{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:28:12Z","timestamp":1793816892441,"version":"4.6.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Obesity is a chronic, multifactorial disease characterized by excessive adiposity and associated with an increased risk of cardiovascular disease, type 2 diabetes, and reduced quality of life. Despite the widespread adoption of lifestyle interventions, long-term weight maintenance remains challenging, highlighting the need for effective pharmacologic therapies. Recent advances, including the US Food and Drug Administration approval of oral semaglutide, offer new opportunities for patient-centered obesity management. Evidence from the OASIS 1 and OASIS 4 trials demonstrates that oral semaglutide, combined with lifestyle intervention, produces clinically meaningful weight loss in adults with overweight or obesity without type 2 diabetes, while improving physical function and cardiometabolic risk markers, such as waist circumference, lipids, and inflammatory parameters. These trials further underscore the benefits of an oral formulation in improving accessibility and adherence compared with injectable therapies. Collectively, oral semaglutide represents a significant advancement in obesity pharmacotherapy, complementing lifestyle interventions and providing both metabolic and functional benefits. Future studies addressing long-term efficacy, cardiovascular outcomes, comparative effectiveness with other agents, and real-world implementation will be essential to fully define its role in comprehensive, individualized obesity care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005161","type":"journal-article","created":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:01:27Z","timestamp":1793815287000},"page":"6244-6248","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advances in pharmacologic management of obesity: oral semaglutide for weight management"],"prefix":"10.1097","volume":"88","author":[{"given":"Fnu","family":"Zainab","sequence":"first","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9913-0509","authenticated-orcid":false,"given":"Abdul Haseeb","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"},{"name":"Department of Research, Oli Health Magazine Organization, Kigali, Rwanda"},{"name":"Department of Internal Medicine, Sentara Northern Virginia Medical Center, Woodbridge, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"1027\u201350","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"284\u201391","DOI":"10.7861\/clinmed.2023-0168","article-title":"Causes of obesity: a review","volume":"23","author":"Masood","year":"2023","journal-title":"Clin Med"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"482\u2013501","DOI":"10.1007\/s13679-023-00526-z","article-title":"Genetics and epigenetics in obesity: what do we know so far?","volume":"12","author":"Keller","year":"2023","journal-title":"Curr Obes Rep"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"18\u201327","DOI":"10.1007\/s13679-017-0240-4","article-title":"Endocrine disruptors and obesity","volume":"6","author":"Darbre","year":"2017","journal-title":"Curr Obes Rep"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"440\u201348","DOI":"10.3949\/ccjm.88a.20080","article-title":"Antiobesity drug therapy: an individualized and comprehensive approach","volume":"88","author":"Mauer","year":"2021","journal-title":"Cleve Clin J Med"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"544\u201351","DOI":"10.1038\/oby.2001.71","article-title":"Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women","volume":"9","author":"Gadde","year":"2001","journal-title":"Obes Res"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"156\u201364","DOI":"10.1007\/s13679-019-00335-3","article-title":"Metformin: mechanisms in human obesity and weight loss","volume":"8","author":"Yerevanian","year":"2019","journal-title":"Curr Obes Rep"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"705\u201319","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"1077\u201387","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral Semaglutide At A Dose Of 25 Mg In Adults With Overweight Or Obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"R26-20261104","first-page":"860\u201367","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"1331\u201333","DOI":"10.4093\/dmj.2025.0666","article-title":"Bridging efficacy and adherence in glucagon-like peptide-1 receptor agonist therapy: the emerging role of oral agents","volume":"49","author":"Wang","year":"2025","journal-title":"Diabetes Metab J"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"1593334","DOI":"10.3389\/fendo.2025.1593334","article-title":"Oral semaglutide for the treatment of obesity: a retrospective real-world study","volume":"16","author":"Krajnc","year":"2025","journal-title":"Front Endocrinol"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"159\u201366","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"2805\u201322","DOI":"10.1097\/JS9.0000000000004413","article-title":"Current concerns and future directions of large language model ChatGPT in medicine: a machine-learning-driven global-scale bibliometric analysis","volume":"112","author":"Guo","year":"2026","journal-title":"Int J Surg"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:01:29Z","timestamp":1793815289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005161","relation":{},"ISSN":["2049-0801","2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"},{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"2026-02-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}